Kure Cells

Kure.ai (formerly Kure Cells) is a San Francisco-based biotechnology company that leverages artificial intelligence to design and optimize next-generation cell therapies for cancer and autoimmune diseases. The company's proprietary platform integrates machine learning with high-throughput screening to engineer T-cells with enhanced persistence, potency, and specificity, specifically addressing the challenges of treating solid tumors. By focusing on the 'dark matter' of the genome and protein-protein interactions, Kure.ai aims to overcome the limitations of current CAR-T therapies. Their pipeline includes several early-stage programs targeting both liquid and solid malignancies, such as CD19, BCMA, and GPC3. The company is backed by prominent venture capital firms like 8VC and is led by a team of experts from UC Berkeley.